Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Guillermo Ballarino

Pulmonary Disease Danbury, CT Medical Doctor

NPI 1386810802 CMS profile 334805

24 Hospital Ave, Fl 1, Danbury, CT 06810

Open in the dashboard

General payments

$3,528

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,295 paid to institutions, not to them · program year 2019

Through program year 2025, Guillermo Ballarino of Danbury, CT is reported in the CMS Open Payments database as having received $3,528 across 36 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,295 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 61st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $102 5
2024 General $1,043 8
2023 General $1,569 13
2022 General $730 7
2020 General $66 2
2019 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guillermo Ballarino
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Guillermo Ballarino were reported at $102. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Guillermo Ballarino Pulmonary Disease median Middle half National median
2019 $18 $377 $109–$1,340 $163
2020 $66 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $730 $390 $100–$1,457 $149
2023 $1,569 $419 $114–$1,659 $160
2024 $1,043 $476 $123–$1,818 $164
2025 $102 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $2,587 20 payments
  2. Ethicon Inc. $715 6 payments
  3. GlaxoSmithKline, LLC. $55 3 payments
  4. Genentech USA, Inc. $48 1 payment
  5. Verona Pharma, Inc. $28 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $25 1 payment
  7. Insmed, Inc. $20 1 payment
  8. Jazz Pharmaceuticals Inc. $18 1 payment
  9. Seattle Genetics, Inc. $18 1 payment
  10. Pfizer Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,658 12 payments
  2. Food and Beverage $823 23 payments
  3. Education $48 1 payment
Products named General payments · program years 2019–2025
  1. Monarch $1,513 13 payments
  2. Monarch Platform $715 6 payments
  3. NUCALA $55 3 payments
  4. Esbriet $48 1 payment
  5. Ohtuvayre $28 1 payment
  6. GLASSIA $25 1 payment
  7. Arikayce $20 1 payment
  8. XYREM $18 1 payment
  9. SUNOSI $18 1 payment
  10. ADCETRIS $18 1 payment
  11. Other $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,355

Median for Pulmonary Disease: 936

Drug cost

$852,967

Median for Pulmonary Disease: $487,987

Branded share of claims

74.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 281 $254,535
Opsumit Macitentan Brand 12 $148,312
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 206 $143,805
Breo Ellipta Fluticasone/Vilanterol Brand 135 $85,853
Xolair Omalizumab Brand 18 $62,648
Pirfenidone Generic 12 $57,075
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 24 $19,629
Spiriva Respimat Tiotropium Bromide Brand 16 $17,622
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $13,029
Arnuity Ellipta Fluticasone Furoate Brand 27 $11,897

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$117,900

Of which drugs: $1,546

Medicare patients

582

Average age 76

Services billed

1,517

309 women, 273 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 49%
COPD 46%
Diabetes 37%
Chronic kidney disease 36%
Atrial fibrillation 34%
Heart failure 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record